Julien’s Primer of Drug Action continues to evolve side by side with the field it covers providing a thoroughly up to date look at psychotherapeutic and recreational drugs, including the latest research and the newest formulations. The thoroughly updated 14th edition features: New coverage of opioids of abuse, and drugs used to treat of opioid dependence and opioid overdose. New research on the use of marijuana to treat Alzheimers, PTSD, and Epilepsy. New coverage of pharmacological, physiological, and psychoactive effects of synthetic marijuana including its toxicity. New research on Cannabidiol (CBD) and its therapeutic uses New research of the efficacy of antipsychotics to treat dementia, Parkinson’s, bipolar, OCD, PTSD, New research on hallucinogenics for the treatment of various disorders including MDMA for the treatment of PTSD, Psilocybin for treatment of depression and end-of-life anxiety, and Ayahuasca to treat psychiatric disorders The use of genetic testing to predict effectiveness of antidepressant treatment New research on the use of ketamine for the treatment of depression

This book is a guide for psychiatrists struggling to incorporate transformational strategies into their clinical work. The book begins with an overview of the concept of critical psychiatry before focusing its analytic lens on the DSM diagnostic system, the influence of the pharmaceutical industry, the crucial distinction between drug-centered and disease-centered approaches to pharmacotherapy, the concept of “de-prescribing,” coercion in psychiatric practice, and a range of other issues that constitute the targets of contemporary critiques of psychiatric theory and practice. Written by experts in each topic, this is the first book to explicate what has come to be called critical psychiatry from an unbiased and clinically relevant perspective. Critical Psychiatry is an excellent, practical resource for clinicians seeking a solid foundation in the contemporary controversies within the field. General and forensic psychiatrists; family physicians, internists, and pediatricians who treat psychiatric patients; and mental health clinicians outside of medicine will all benefit from its conceptual insights and concrete advice.

Presents a user-friendly step-by-step manual on the psychotropic drugs prescribed for children and adolescents by clinicians and nurse practitioners.

The National Survey of Child and Adolescent Well-Being (NSCAW) is the first nationally representative study of children who have been reported to authorities as suspected victims of abuse or neglect and the public programs that protect them. Child Protection is the first book that reports the results of NSCAW, interprets the findings, and puts them into a broader policy context. The authors, all experts in child welfare issues, address a range of issues made apparent by the survey results, including which types of personal and familial problems the programs are meant to address, the range of services and interventions that the child protection system can make available, and an assessment of these programs. Each chapter discusses the survey's implications and suggests new alternatives for designing and implementing future programs that not only protect at-risk children from further harm but also provide them with security and support. The practical lessons included in this volume make it an essential reference for all professionals working in the child protection field as well as anyone studying in the field of child welfare.

Estimates indicate that as many as 1 in 4 Americans will experience a mental health problem or will misuse alcohol or drugs in their lifetimes. These disorders are among the most highly stigmatized health conditions in the United States, and they remain barriers to full participation in society in areas as basic as education, housing, and employment. Improving the lives of people with mental health and substance abuse disorders has been a priority in the United States for more than 50 years. The Community Mental Health Act of 1963 is considered a major turning point in America's efforts to improve behavioral healthcare. It ushered in an era of optimism and hope and laid the groundwork for the consumer movement and new models of recovery. The consumer movement gave voice to people with mental and substance use disorders and brought their perspectives and experience into national discussions about mental health. However over the same 50-year period, positive change in American public attitudes and beliefs about mental and substance use disorders has lagged behind these advances. Stigma is a complex social phenomenon based on a relationship between an attribute and a stereotype that assigns undesirable labels, qualities, and behaviors to a person with that attribute. Labeled individuals are then socially devalued, which leads to inequality and discrimination. This report contributes to national efforts to understand and change attitudes, beliefs and behaviors that can lead to stigma and discrimination. Changing stigma in a lasting way will require coordinated efforts, which are based on the best possible evidence, supported at the national level with multiyear funding, and planned and implemented by an effective coalition of representative stakeholders. Ending Discrimination Against People with Mental and Substance Use Disorders: The Evidence for Stigma Change explores stigma and discrimination faced by individuals with mental or substance use disorders and recommends effective strategies for reducing stigma and encouraging people to seek treatment and other supportive services. It offers a set of conclusions and recommendations about successful stigma change strategies and the research needed to inform and evaluate these efforts in the United States.

A critical investigation into the use of psychotropic drugs to pacify and control inmates and other captives in the vast U.S. prison, military, and welfare systems For at least four decades, U.S. prisons and jails have aggressively turned to psychotropic drugs—antidepressants, antipsychotics, sedatives, and tranquilizers—to silence inmates, whether or not they have been diagnosed with mental illnesses. In Silent Cells, Anthony Ryan Hatch demonstrates that the pervasive use of psychotropic drugs has not only defined and enabled mass incarceration but has also become central to other forms of captivity, including foster homes, military and immigrant detention centers, and nursing homes. Silent Cells shows how, in shockingly large numbers, federal, state, and local governments and government-authorized private agencies pacify people with drugs, uncovering patterns of institutional violence that threaten basic human and civil rights. Drawing on publicly available records, Hatch unearths the coercive ways that psychotropics serve to manufacture compliance and docility, practices hidden behind layers of state secrecy, medical complicity, and corporate profiteering. Psychotropics, Hatch shows, are integral to “technocorrectional” policies devised to minimize public costs and increase the private profitability of mass captivity while guaranteeing public safety and national security. This broad indictment of psychotropics is therefore animated by a radical counterfactual question: would incarceration on the scale practiced in the United States even be possible without psychotropics?